Arterial occlusive disease is the leading cause of death in Western countries. Core
contemporary therapies for this disease include angioplasties, stents, endarterectomies and …

Objective There have been concerns about the long term safety of paclitaxel coated devices
in the lower limbs. A formal systematic review and meta-analysis of randomised controlled …

Background The results of a recent meta-analysis aroused concern about an increased risk
of death associated with the use of paclitaxel-coated angioplasty balloons and stents in …

Importance Paclitaxel-coated peripheral devices have been associated with increased
mortality, yet this harm signal has not been replicated outside of meta-analyses of small …

Background Numerous randomised clinical trials and real-world studies have supported the
safety of paclitaxel-coated devices for the treatment of femoropopliteal occlusive disease …

Objectives This study sought to evaluate the safety and effectiveness of the Ranger drug-
coated balloon (DCB)(paclitaxel dose density 2 μg/mm2) for treating superficial femoral …

Purpose: To report the 36-month outcomes from the prospective, multicenter, single-arm IN.
PACT Global Study (ClinicalTrials. gov identifier NCT01609296) evaluating the performance …

Purpose: A late increased mortality risk has been reported in a summary level meta-analysis
of patients with femoropopliteal artery occlusive disease treated with paclitaxel-coated …

Background Intimal hyperplasia (IH) remains a major limitation in the long-term success of
any type of revascularisation. IH is due to vascular smooth muscle cell (VSMC) …

Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower
extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been …